Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab in Pediatric Primary HLH
NCT01818492Phase 3Completed
- Sponsor
- Sobi
- Start
- Jul 2013
- Primary completion
- Jan 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of emapalumab in primary hemophagocytic lymphohistiocytosis (HLH), sponsored by Sobi. Primary endpoints: Overall Response Rate (ORR) Second Line, Overall Response Rate (ORR) All Treated and 2 more. Started Jul 2013; status: completed.
02
Drugs
emapalumab
03
Conditions
primary hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT01818492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01818492.